Abhijeet Patra

@patra

All cardsCollections

https://t.co/wNd8jnZelU

Dr. Shelby x.com

clinicaltrials

What I did wrong with Artemis | Alex S. Araki

linkedin.com

postmortem

Don’t watch a movie this weekend watch this

Alexis Ohanian 🗽x.com

coding

linkedin.com

Debunk

I had it in my 'to-watch' list for some time now, and used this relaxing Sunday evening to finally watch Phil Sharp's doc from PBS, and it was phenomenal. Following...

linkedin.com

Thumbnail of I had it in my 'to-watch' list for some time now, and used this relaxing Sunday evening to finally watch Phil Sharp's doc from PBS, and it was phenomenal. Following...

It’s not often I find The Economist writing something economically absurd, and yet, check this out. In an article about how AI will increase drug R&D success rates, they suggest...

linkedin.com

Thumbnail of It’s not often I find The Economist writing something economically absurd, and yet, check this out. In an article about how AI will increase drug R&D success rates, they suggest...

Debunk

Introducing my new book “The Art of Crafting Prompts: An Interactive Guide To Mastering Chat GPT With MindBranches” Quickly learn: • Strategies for thinking with AI • Keys to effective prompting • How to make MindBranches Packed with exercises and... See more

MindBranches x.com

prompting

Opportunities for Rare Diseases to Drive Growth in Big Pharma | L.E.K. Consulting | Rabia T. K.

linkedin.com

We are witnessing a historic decoupling of biotech value from the Big Pharma acquisition cycle. The traditional venture "exit" (from Phase1/2 post-PoC M&A or an IPO) is being replaced by independent… | Paras Sharma

linkedin.com

Thumbnail of We are witnessing a historic decoupling of biotech value from the Big Pharma acquisition cycle. The traditional venture "exit" (from Phase1/2 post-PoC M&A or an IPO) is being replaced by independent… | Paras Sharma

Biotech ipo

What I did wrong with Artemis | Alex S. Araki

I had it in my 'to-watch' list for some time now, and used this relaxing Sunday evening to finally watch Phil Sharp's doc from PBS, and it was phenomenal. Following...

It’s not often I find The Economist writing something economically absurd, and yet, check this out. In an article about how AI will increase drug R&D success rates, they suggest...

Opportunities for Rare Diseases to Drive Growth in Big Pharma | L.E.K. Consulting | Rabia T. K.

We are witnessing a historic decoupling of biotech value from the Big Pharma acquisition cycle. The traditional venture &quot;exit&quot; (from Phase1/2 post-PoC M&amp;A or an IPO) is being replaced by independent… | Paras Sharma

We are witnessing a historic decoupling of biotech value from the Big Pharma acquisition cycle. The traditional venture "exit" (from Phase1/2 post-PoC M&A or an IPO) is being replaced by independent… | Paras Sharma